Yonsei Med J.  2024 Oct;65(10):619-622. 10.3349/ymj.2023.0540.

A Case Report of Lenacapavir Use in a Patient with Multidrug-Resistant HIV: The First Experience in Asia

• Lee Y
• Lee KH
• Lee JA
• Ahn SM
• Han M
• Choi JY

• KMID: 2559668
• DOI: http://doi.org/10.3349/ymj.2023.0540

Abstract

Lenacapavir is a novel, first-in-class, capsid inhibitor, which has been approved as an adjunctive therapy for multidrug-resistant human immunodeficiency virus (HIV)-1 virus in combination with optimized background regimen (OBR). Lenacapavir has demonstrated a significant decrease in viral load and high rate of virologic suppression in patients with multidrug-resistant HIV-1 infection with limited treatment options. Here, we report a case of 43-year-old male who was diagnosed with HIV-1 infection in 2005 but failed to achieve viral suppression due to multiclass resistance. After lenacapavir use with OBR, viral suppression was achieved, and recovery of CD4 + T-cell count was observed for 8 months. This case report shows the first lenacapavir experience in Asia in a heavily treatment-experienced HIV patient with limited treatment options.

Keyword

HIV; acquired immunodeficiency syndrome; drug resistance; anti-retroviral agents